Daily evidence digest
3 March 2022

The daily evidence digest collates recently released reports and evidence — provision of these links does not imply endorsement nor recommendation.

Remdesivir for COVID-19 adults, COVID-19 infection in adults with intellectual disabilities, prescribing nirmatrelvir–ritonavir (PAXLOVID)

Peer reviewed journals featured:
- Systematic reviews on:
  - Remdesivir for adults with COVID-19 [here](#) and practice points [here](#)
  - SARS-CoV-2 detection in saliva collected passively without forceful coughing [here](#)
  - Humoral immune response 6 months post mRNA vaccination [here](#)
- Observational studies on:
  - COVID-19 infection and outcomes in adults with intellectual disabilities [here](#)
  - Long COVID (post-acute COVID-19 syndrome) in Northwest Spain [here](#)
  - COVID-19 post-acute sequelae [here](#)
  - Pupil-to-pupil SARS-CoV-2 transmission and the impact of lateral flow testing in English secondary schools [here](#)
- Commentary on prescribing nirmatrelvir–ritonavir (PAXLOVID) [here](#)

Pre-peer review articles featured:
- Comparison of rapid antigen tests’ performance between Delta and Omicron (B.1.1.529; BA1) [here](#)
- Different efficacies of neutralising antibodies and antiviral drugs on Omicron subvariants [here](#)
- Medium-term impacts of COVID-19 waves on treating non-COVID-19 patients in ICU in Japan [here](#)
- Effect of booster vaccination against Delta and Omicron variants in Iceland [here](#)
- Disparity between national and institution-based testing for case detection [here](#)

Guidance and reports
- The World Health Organization published:
  - Recommendations on safe schooling during COVID-19 [here](#)

News and blogs
- Hundreds of COVID-19 trials could provide a deluge of new drugs [here](#)